Bocci V
Institute of General Physiology and Nutritional Science, University of Siena, Italy.
J Biol Regul Homeost Agents. 1993 Jan-Mar;7(1):1-6.
Therapy of cancer with a Viscum extract has been carried out in Europe for over six decades in thousands of patients with uncertain advantages. This approach has been bedeviled by major problems such as variable composition of the extract, lack of knowledge of active component(s) and mechanism of action, to cite a few. However the recent standardization of Viscumin in terms of galactoside-binding lectin activity has allowed to clarify that it can act as powerful inflammatory mediator able to stimulate the immune system. Merits and demerits of this approach have been reviewed and although the active component has probably not unique immunoenhancing properties, it may be useful as an adjuvant in the biological therapy of cancer and it should not be ignored any longer. As usual, medical progress depends upon experimentation and not exclusively on intuition and emotion.
在欧洲，用槲寄生提取物治疗癌症已有六十多年，涉及数千名患者，但疗效尚不明确。这种方法存在诸多重大问题，比如提取物成分多变、活性成分及作用机制不明等等。然而，近期对细胞凝集素在半乳糖苷结合活性方面的标准化，已明确其可作为强大的炎症介质刺激免疫系统。本文回顾了该方法的优缺点，尽管活性成分可能并非具有独特的免疫增强特性，但它或许可作为癌症生物治疗的辅助药物，不应再被忽视。一如既往，医学进步依赖实验，而非仅靠直觉和情感。
